technology.merinews.com —Japanese major Daiichi Sankyo is all set to buy out Ranbaxy, paying anything between 30 per cent and 50 per cent premium for the pharmaceutical company. It would mean the complete exit of Ranbaxy promoters from the company.
Digg is a place for people to discover and share content from anywhere on the web. Digg surfaces the best stuff as submitted and voted on by the community. Take the Tour to learn more.